Reduced Expression of DACT2 Promotes Hepatocellular Carcinoma Progression: Involvement of Methylation-Mediated Gene Silencing

Sheng Gao,Zhe Yang,Zhi-Yun Zheng,Jia Yao,Feng Zhang,Li-Ming Wu,Hai-Yang Xie,Lin zhou,Shu-Sen Zheng
DOI: https://doi.org/10.1186/1477-7819-11-57
2013-01-01
World Journal of Surgical Oncology
Abstract:Background Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in humans, and its prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of HCC; however, the molecular mechanisms that lead to hepatocarcinogenesis and progression are still not clearly understood. Methods The expression of DACT2 in specimens from 30 paired HCCs and an additional 61 HCC patients after liver transplantation was evaluated by quantitative RT-PCR and immunohistochemical analysis. We investigated the methylation status of the DACT2 promoter region. We also analyzed the alterations of the cell cycle, migration and invasion after DACT2 knockdown. Results The expression level of DACT2 was significantly lower in HCC tissues than in non-cancerous tissues. Reduced DACT2 expression was associated with large tumor size. DACT2 transcripts were at low levels in hypermethylated liver cancer cells and were restored by exposure to a demethylating agent. Reduced expression of DACT2 in MHCC97L cells induced G1/S arrest, increased cell proliferation, and promoted cell invasion. Conclusions Our study suggests that DACT2 is silenced by promoter hypermethylation, and reduced DACT2 can promote liver cancer progression. DACT2 may serve as a novel tumor suppressor gene in HCC.
What problem does this paper attempt to address?